Enhancing CAR-T efficacy for targeting lymphoma and solid tumors
Sponsor
Most patients treated with FDA approved CAR-T cells eventually experience disease progression. Furthermore, CAR-T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses.
One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR-T cell dysfunction and lack of expansion and/or persistence after infusion. In this webinar, you will learn more about technology to enhance CAR-T efficacy developed by Dr Marco Ruella’s lab and ViTToria Biotherapeutics. We will deep dive into how CD5 inhibits CAR-T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR-T cells in multiple hematological and solid cancer models. Additionally, you will learn about the development of rapid manufacturing process which can enhance the T cell functioning in targeting cancer.
Attend this webinar to learn about:
- The impact of CD5 deletion on T cell signalling
- Pre-clinical in vivo and in vitro data in several cancer models
- Comparing rapid manufacturing process vs traditional 12 days manufacturing process, and learnings from developing a rapid manufacturing process
- Translating the process from early research to clinical GMP setting
SPEAKERS
You might also like
Advancing TCR-based therapies: discovery, analysis, and QC of Ag-specific T cells targeting solid cancers
Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies
Key considerations for shortening your CAR-T manufacturing process
